The HealthTree Foundation has announced the launch of the new AI-powered personalised Clinical Trial Finder, designed to match multiple myeloma (MM) patients with suitable trials.
This feature, now part of the HealthTree Cure Hub Registry, leverages AI to enhance the process of connecting subjects with potential treatment options in clinical trials depending on their medical records.
Go deeper with GlobalData
HealthTree Foundation CTO Juan Pablo Capdevila said: “We are able to power the HealthTree Clinical Trial Finder with clean, validated, and organised data thanks to our use of AI.
“This enables real-time analysis of the data against continuously updated trial databases for instant matching.”
For individuals with MM, the task of locating a relevant clinical trial can be time-consuming due to the complexity of trial eligibility criteria.
The HealthTree Clinical Trial Finder aims to alleviate this challenge by individual medical records analysis, which includes laboratory values, disease markers and treatment history, to identify trials for which a patient is eligible.
According to the organisation, this service not only helps subjects explore all available treatment avenues but also streamlines the search time for clinicians and expedites the enrolment process for studies, potentially speeding up the discovery of new cures.
HealthTree Founder and CEO Jenny Ahlstrom said: “This is the first truly personalised clinical trial finder. Unlike common clinical trial finders that allow patients to search for trials based on filters like zip code or treatment type, we are using tens of thousands of data points to ensure that patients receive personalised trial matches based on their real-world medical data.”
A non-profit organisation, the HealthTree Foundation is focused on enhancing outcomes and discovering cures for blood cancers via patient education, research partnership, and technology.
The organisation’s HealthTree Cure Hub is a data portal of patients, which has gathered real-world data from over 10,000 individuals, thereby allowing researchers to make advances in the field.
